Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacologic Class In Label Should Be Set By Formulary, Not Industry – ASHP

Executive Summary

A recent FDA draft guidance that leaves pharmacologic class determination in the hands of drug manufacturers has led the American Society of Health-System Pharmacists to offer its American Hospital Formulary System classification as an alternative

You may also be interested in...



Draft Guidance Explains Inclusion Of Pharmacologic Class In New Labeling

FDA's standards for an "established" pharmacologic class are that the agency has determined the class is both scientifically valid and clinically meaningful, according to a draft guidance released May 15

USP To Finalize Medicare Rx Model Formulary In 2004; VA System As Guide?

The Veterans Affairs medication classification system is likely to serve as a starting point for the U.S. Pharmacopeia's development of a model formulary for the Medicare prescription drug benefit

IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns

The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel